The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?

Softgel capsule manufacturing technologies

Overcome drug product development challenges with propriety softgel products

Whether your product has solubility issues—as do 70% of drugs in development—or your brand is looking to expand shelf space, softgels may be the best finished dosage solution. With fierce competition among CDMOs in the United States, Europe, and Asia, choosing the right partner to develop your prescription therapeutics (Rx) or consumer healthcare product can be a difficult decision.

We bring decades of experience from development through commercialization and have dedicated encapsulation facilities in High Point, NC, and Tilburg, the Netherlands, have the capacity to produce 10 billion to 12 billion softgels annually. Our scientists are skilled in developing softgel formulations in early development to overcome bioavailability challenges and speeding new molecules to clinic. We also develop softgel formulations for late-stage lifecycle management, helping our clients retain market share and maximize product lifetime value.

No. 1

The No. 1 preferred provider of CDMO services for small molecule drug product manufacturing,1 offering a consultative experience to bring your small molecule to market in the form of a softgel

78 new OTC softgel projects

Over the last five years, Patheon pharma service has started 78 new over-the-counter (OTC) softgel projects. 

20 tech transfers

In 2022, Patheon pharma services successfully completed 20 small molecule tech transfers (all therapeutic areas)

View references
1. 2021 ISR report: ISR Reports. Small Molecule Drug Product: Contract Manufacturer Quality Benchmarking. 4th edition, January 2021, p. 28. (Data collected in Q3 2020.)Instructions and permissions to use: N/A

Softgel advantages

Rx advantages

  • Improve solubility and bioavailability of poorly soluble actives
  • Improve containment of highly potent API (cat 3a, 3b, and hormones)
  • Precise control of drug release rate, content uniformity, and site of absorption
  • Anti-counterfeiting technologies
  • Rapidly scalable across development to commercial
  • Ideal for light-sensitive and oxygen-sensitive APIs 

Consumer healthcare advantages

  • Develop product proof of concept to confirm market interest
  • Provide line extension for product lifecycle management
  • Unique product differentiation and branding with proprietary technologies
  • Solutions for tablet to softgel switches
  • Enhance bioavailability to obtain quicker onset of action
  • Formulation options geared toward patient preferences

 

Discover the benefits of softgels and our diverse technologies that can meet the needs of your molecules and markets.